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A B S T R A C T
Purpose
This study aimed to evaluate racial/ethnic differences in lung cancer incidence and mortality in the
Women’s Health Initiative Study, a longitudinal prospective cohort evaluation of postmenopausal
women recruited from 40 clinical centers.
Methods
Lung cancer diagnoses were centrally adjudicated by pathology review. Baseline survey ques-
tionnaires collected sociodemographic and health information. Logistic regression models esti-
mated incidence andmortality odds by race/ethnicity adjusted for age, education, calcium/vitamin D,
bodymass index, smoking (status, age at start, duration, and pack-years), alcohol, family history, oral
contraceptive, hormones, physical activity, and diet.
Results
The cohort included 129,951 women—108,487 (83%) non-Hispanic white (NHW); 10,892 (8%) non-
Hispanic black (NHB); 4,882 (4%) Hispanic; 3,696 (3%) Asian/Pacific Islander (API); 534 (, 1%)
American Indian/Alaskan Native; and 1,994 (1%) other. In unadjusted models, Hispanics had 66%
lower odds of lung cancer compared with NHW (odds ratio [OR], 0.34; 95% CI, 0.2 to 0.5), followed
by API (OR, 0.45; 95% CI, 0.27 to 0.75) and NHB (OR, 0.75; 95% CI, 0.59 to 0.95). In fully adjusted
multivariable models, the decreased lung cancer risk for Hispanic compared with NHW women
attenuated to the null (OR, 0.59; 95% CI, 0.35 to 0.99). In unadjusted models Hispanic and API
women had decreased risk of death compared with NHW women (OR, 0.30 [95% CI, 0.15 to 0.62]
and 0.34 [95% CI, 0.16 to 0.75, respectively); however, no racial/ethnic differences were found in
risk of lung cancer death in fully adjusted models.
Conclusion
Differences in lung cancer incidence and mortality are associated with sociodemographic, clinical,
and behavioral factors. These findings suggest modifiable exposures and behaviors may contribute
to differences in incidence of and mortality by race/ethnicity for postmenopausal women. Inter-
ventions focused on these factors may reduce racial/ethnic differences in lung cancer incidence and
mortality.
J Clin Oncol 34:360-368. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Worldwide, lung cancer is a leading cause of
cancer incidence and death.1,2 Disparities in lung
cancer incidence and mortality have been pre-
viously reported in several cohort studies
worldwide. These studies demonstrate the highest
rates among non-Hispanic black (NHB) pop-
ulations3-6 and the lowest rates among Hispanic7,8
and Asian populations.9-11 Although these
findings are consistent with those reported
among men in the United States,3,4,12,13 these
discrepancies have not been as well-described
among women.
The few studies among US women are
inconsistent; some reported increased incidence
and mortality among non-Hispanic white (NHW)
women compared with other racial/ethnic
groups4,14 and others showed increased incidence
in NHB women.13,15,16 Some smaller-sample-size
studies that adjusted for age, socioeconomic status,
and smoking demonstrated similar incidences
among NHW and NHB women.17-22 Other
studies suggested that differences depend on pack-
years smoked. For example, the Multi-Ethnic
360 © 2015 by American Society of Clinical Oncology
VOLUME 34 • NUMBER 4 • FEBRUARY 1, 2016
Cohort study revealed an increased incidence among NHB women
who smoke fewer than 30 cigarettes daily compared with NHW
women, and that differences no longer persist in women who
smoke more than 30 cigarettes daily.18 In this same study, con-
sistent with other investigations,23,24 Japanese-American and
Hispanic women had lower incidence than NHW women, which
was thought to be due to decreased smoking rates.18 In the few
studies that evaluated mortality, age-adjusted models demon-
strated that mortality is similar among NHB and NHWwomen.3,25
However, one study demonstrated that NHB women younger than
65 years have decreased 5-year survival compared with NHW
women.26
Inconsistencies in the existing literature on racial and ethnic
differences in lung cancer incidence and mortality may be due to
the lack of inclusion of various risk factors. In this study, we sought
to investigate the influence of sociodemographic, clinical, and
behavioral risks on lung cancer incidence and mortality in the
Women’s Health Initiative (WHI). Our aim was to determine
whether differences exist in lung cancer incidence and mortality
among women by race/ethnicity in a prospective cohort.
METHODS
The WHI, a multiethnic, prospective, longitudinal cohort study of the
major risk factors that affect postmenopausal women’s health, includes
observational study (OS) and clinical trial (CT) arms. The study design,
described previously, included women at 40 US clinical centers.27,28
Postmenopausal women were eligible if they were age 50 to 79 years,
were unlikely to relocate or die within 3 years, were without certain
complicating conditions, and provided written consent. The CT arms
evaluated effects of hormones, diet, and calcium and vitamin D supple-
mentation, and women could choose to participate in one, two, or all three
of the components. Women ineligible or unwilling to join the CT arms
were invited to enroll on the OS, which examined association of baseline
lifestyle, health, and risk factors on disease outcomes. Inclusion of the OS
and CT arms provides an increased sample size that enhances the asso-
ciations of behavioral patterns on lung cancer incidence and mortality.
Baseline Data Collection
Self-administered questionnaires were used to collect baseline
demographic, medical, reproductive, and family history. Physical activity
was obtained as metabolic equivalent of tasks (MET). Food intake was
obtained by a semiquantitative food frequency questionnaire.
Behaviors such as smoking and alcohol use were also obtained
through baseline questionnaires. Never smoking was defined as having
smoked fewer than 100 cigarettes in a lifetime; past smokers was defined as
those who had smoked 100 or more cigarettes but had not reported
smoking at baseline; current smokers was defined as those who reported
smoking at baseline. Additional information obtained from past smokers
and current smokers included age of smoking initiation, cigarettes/day,
years of smoking, and age of smoking cessation (past smokers only). Pack-
years were calculated by multiplying cigarettes/day by the number of years
smoked, divided by 20 (average cigarettes/pack). Nonsmokers were defined
as having smoked zero pack-years; light smokers, fewer than 20 pack-years;
and heavy smokers, 20 or more pack-years.
Information regarding hormone therapy use (defined as use of
estrogen-containing agents for at least 3 months and additionally classified
as estrogen alone or combination estrogen/progestin), oral contraceptives,
and other medications, including dietary supplements, also was obtained.
Information about race/ethnicity was self-reported as NHW, NHB, His-
panic, Asian/Pacific Islander (API), American Indian/Alaskan Native
(AIAN), and other.
Follow-Up and Lung Cancer Ascertainment
Lung cancer diagnoses were collected annually for OS participants
and semiannually for CT participants. Self-reports or next-of-kin (proxy)
reports of lung cancer events were verified by centrally trained WHI
physician adjudicators at the Clinical Centers after review of the medical
and pathology records by using the Surveillance Epidemiology and End
Results (SEER) coding system. Cancer-specific mortality was defined as
lung cancer deaths and also was recorded if the patient had a lung cancer
diagnosis and the cause of death was entered as other cancer if it was not
specifically recorded as lung cancer. Participants were enrolled from 1993
until 1998, and follow-up lasted through 2009.
Statistical Analyses
Primary analyses were designed to address relationships between
race/ethnicity and risk for incidence and mortality. Of secondary interest
was the relationship between race/ethnicity and cancer subtype. We used
logistic regression models to estimate odds ratios and 95% CIs for inci-
dence and mortality by race/ethnicity because of the anticipated small cell
sizes. The first model (model 1) was unadjusted; subsequent models were
adjusted for age as a continuous covariate (model 2); adjusted additionally
for smoking (model 3); and adjusted for all potential confounders at
baseline (model 4), which were selected a priori on the basis of established
and hypothesized risk factors. Potential confounders were included as
covariates in the model; these included both smoking-related (age at
initiation duration, pack-years, smoking status) and non–smoking-related
(age, education, calcium and/or vitamin D supplementation, body mass
index [BMI], alcohol use, OS or CTmembership and random assignment
status if enrolled in CT, family history of cancer, oral contraceptive use,
hormone use, physical activity, and diet [fruit, vegetable, and meat
Eligible cohort:
N = 161,808
n = 93,676 from OS
n = 68,132 from CT
n = 413 total excluded for
missing outcomes:
n = 265 excluded
from OS
n = 148 excluded
from CT
n = 161,395
n = 93,411 excluded
from OS
n = 67,984 excluded
from CT
n = 31,444 total excluded for
missing confounders:
n = 16,253 excluded
from OS
n = 15,191 excluded
from CT
Analytic Cohort:
N = 129,951
n = 77,158 excluded
from OS
n = 52,793 excluded
from CT
Fig 1. Cohort sample size flow chart, Women’s Health Initiative. CT, clinical trial;
OS, observational study.
www.jco.org © 2015 by American Society of Clinical Oncology 361
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consumptions]) characteristics. Because it is possible that race/ethnicity-
specific risk is modified by smoking intensity, correlation between stage
and race/ethnicity among incident cases was examined with Wald x2 tests.
Models were fit with an interaction term between smoking intensity
(heavy, light, nonsmoker) and race/ethnicity. These interactions were not
significant, so they were dropped from final models.
In secondary analyses, we examined associations between histologic
subtype and race/ethnicity, for which histologic subtype was defined as no
cancer diagnosed, small-cell lung cancer, or non–small-cell lung cancer.
Multinomial regression was used to explore associations between race/
ethnicity and histology in a multivariable-adjusted model. Wald tests were
used to assess relevant associations. For example, Wald tests were used to
assess association between stage and race/ethnicity among incident cases
and association between smoking dose and race/ethnicity on incidence and
mortality. All analyses were conducted by using Statistical Analysis Systems
(SAS) for Windows version 9.4. All tests were two tailed, and significance
was defined as P less than .05 and a 95% CI that did not cross or include 1.
RESULTS
There were a total of 161,809 participants enrolled in either the OS
(n = 93,676) or CT (n = 68,132) arms from October 1993 to
December 1998. We excluded patients who had missing outcomes
(n = 265 from OS; n = 148 from CT) and missing covariates (n =
16,253 from OS; n = 15,191 from CT). After exclusions, the total
analytic cohort included 129,951 participants (Fig 1). Of these,
there 108,487 (83%) were NHW; 10,892 (8%) were NHB; 3,696
(3%) were API; 4,882 (4%) were Hispanic; 534 (0.4%) were AIAN;
and 1,460 (1%) women were classified as other race/ethnicity.
Table 1 shows the demographic, health, and lifestyle characteristics
of women by racial/ethnic group. NHW women represented the
oldest racial/ethnic group. NHB, Hispanic, and AIAN women
reported less postsecondary education than NHW women. NHW
and AIAN women reported heavier alcohol use than other groups.
NHW women reported the highest rates of cancer family history.
Hispanic, NHB, and AIAN participants reported fewer METs and
had higher BMIs than API and NHW women. NHW women
reported the most daily fruit and vegetable servings and, along with
AIAN participants, reported the most daily animal protein
consumption.
API and Hispanic women had higher percentages of never-
smoker statuses and lower proportions with a past smoking history
than NHW women. NHB and AIAN women had the highest
proportion of current smoker status compared with other groups.
Most women reported early ages at smoking initiation (younger
than 20 years) and smoking cessation (younger than 45 years).
Reported pack-year smoking history was greatest in NHW women
followed by AIAN women; AIAN women, however, reported the
longest duration of smoking. NHW women had the highest
smoking cessation rates compared with other racial/ethnic groups;
NHB women had the lowest smoking cessation rates.
In our analytic cohort, 1,044 women developed lung cancer;
(NHW, n = 947; NHB, n = 71; API, n = 14; Hispanic, n = 14; AIAN,
n = 4; other, n = 8). Of these, 613 women died at median 10.5 years
of follow up (NHW, n = 550; NHB, n = 42; API, n = 7; Hispanic, n
= 4; AIAN, n = 4).
Incidence odds ratios (ORs) are depicted in Table 2. In
unadjusted models, women from racial/ethnic groups other than
AIAN had statistically significant decreased lung cancer incidence
compared with NHW women (P , .001). Hispanic women had
66% lower odds of incident lung cancer (OR 0.34; 95% CI, 0.2 to
0.5) compared with NHWwomen followed by API (OR, 0.45; 95%
CI, 0.27 to 0.75) and NHB women (OR, 0.75; 95% CI, 0.59 to
0.95). When adjusted for age, there were no differences in inci-
dence for NHB compared with NHW women; however, the lower
incidence among Hispanic and API compared with NHW women
continued to persist and was only slightly attenuated (OR, 0.40
[95% CI, 0.24 to 0.68] and 0.46 [95% CI, 0.27 to 0.77], respec-
tively). In models additionally adjusted for smoking, Hispanic
women continued to have lower incident odds than NHW women
(OR, 0.47; 95% CI, 0.28 to 0.79). In fully adjusted multivariable
models that took into account smoking and other sociodemo-
graphic factors, the decreased risk for Hispanic women compared
with NHW women persisted but was additionally attenuated (OR,
0.59; 95% CI, 0.35 to 0.99). There were no statistically significant
racial/ethnic differences in incidence by histologic subtypes in
adjusted models (Table 3). Association between stage and race/
ethnicity among incident cases was found to be statistically
nonsignificant (P = .56; data not shown).
Table 4 demonstrates mortality ORs. In unadjusted models,
Hispanic and API women had a decreased risk of lung cancer death
compared with NHWwomen (OR, 0.30 [95%CI, 0.15 to 0.62] and
0.34 [95% CI, 0.16 to 0.75], respectively). The decreased risk of
death was also demonstrated in age-adjusted models for Hispanic
and API women (OR, 0.37 [95% CI, 0.18 to 0.76] and 0.36 [95%
Table 2. Lung Cancer Incidence OR Estimates From Logistic Regression Models
Race/
Ethnicity
Unadjusted Age Adjusted Age and Smoking Adjusted Fully Adjusted
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
White 1.00 (Reference) , .001 1.00 (Reference) , .001 1.00 (Reference) , .001 1.00 (Reference) .26
Black 0.75 (0.59 to 0.95) 0.83 (0.65 to 1.05) 0.71 (0.56 to 0.91) 0.85 (0.66 to 1.09)
API 0.45 (0.27 to 0.75) 0.46 (0.27 to 0.77) 0.68 (0.40 to 1.14) 0.74 (0.44 to 1.26)
Hispanic 0.34 (0.20 to 0.57) 0.40 (0.24 to 0.68) 0.47 (0.28 to 0.79) 0.59 (0.35 to 0.99)
AIAN 0.96 (0.38 to 2.44) 1.05 (0.42 to 2.68) 0.92 (0.36 to 2.36) 0.92 (0.36 to 2.36)
Other 0.66 (0.34 to 1.31) 0.68 (0.34 to 1.34) 0.71 (0.36 to 1.40) 0.74 (0.38 to 1.47)
NOTE. Estimates in fully adjusted model were adjusted for age, education, calcium supplementation, vitamin D supplementation, body mass index, age at start of
smoking, duration of smoking habit, pack-years of exposure, smoking status, alcohol use, membership in observational study, hormone replacement therapy or dietary
modification or calcium/vitamin D interventions, family history of cancer, oral contraceptive use, hormone use history, baseline physical activity, and diet (fruit, vegetable
and meat consumption). Data are from the Women’s Health Initiative observational study and clinical trial cohorts.
Abbreviations: AIAN, American Indian/Alaskan Native; API, Asian/Pacific Islander; OR, odds ratio.
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CI, 0.16 to 0.77], respectively) and persisted for Hispanic women
after additional adjustment for smoking (OR, 0.43; 95% CI, 0.21 to
0.89). In fully adjusted models, however, there were no significant
racial/ethnic differences in risk of death.
Table 5 demonstrates incidence and mortality ORs of cova-
riates from logistic regression models. Increasing age, duration of
smoking as measured in years, heavy smoking, current smoking
status (current v never), and family history of cancer were asso-
ciated with an increased risk of incident lung cancer in fully
adjusted models (Table 5). Similarly, in fully adjusted models for
mortality, increasing age, duration of smoking as measured in
years, heavy smoking, and current smoking status (current v never)
were associated with increased risk of lung cancer mortality. BMI
greater than 25 kg/m2 and greater amount of vegetables consumed
were associated with a decreased risk of lung cancer incidence and
mortality.
DISCUSSION
In our study, with the WHI multiethnic cohort, we examined the
influence of sociodemographic, clinical, and behavioral risks on
differences in lung cancer incidence and mortality by race/
ethnicity. We found that, after adjustment for age, Hispanic and
API women had decreased lung cancer incidence and mortality
than NHW women. Only Hispanic women, however, maintained
the mortality advantage compared with NHW women after
additional adjustment for smoking. Differences no longer per-
sisted, however, after additional adjustment for other potential
confounders, including demographic, behavioral (including cur-
rent smoking status, duration of smoking, diet, exercise, and
vitamin and supplement use), and socioeconomic status factors.
Our findings, which differ from studies that consistently dem-
onstrate increased incidence and mortality for NHB men,14,29,30
highlight the importance of sex-specific investigations in lung
cancer.
Our study is in agreement with previously described crude
lung cancer incidence and mortality reports in the United States.14
Our results, which additionally adjust these crude rates for risk
factors and potential confounders, are similar to other studies that
demonstrate equivalent incidence among NHW and NHB
women.31,32 Our results differ from population-based studies that
have shown increased lung cancer incidence among NHB women
after adjustment for age and smoking.13,15,16 Our results differ
from those that show decreased incidence among API women
compared with other racial/ethnic minorities but are consistent
with those that demonstrate decreased incidence among
Hispanics.18,33-35 Our observed decreased lung cancer incidence
risk for Hispanic compared with NHW women in our fully-
adjusted analysis warrants additional investigation.
Our results also differ from previous studies that demonstrate
increased lung cancer mortality among NHW and NHB
women16,36-38 and those that show decreased mortality among
Hispanic and API women compared with other racial/ethnic
groups.34,35 The findings, however, in previous literature on
Hispanic and API women are conflicting, because some show
decreased mortality among Hispanic and API women, whereas
others do not corroborate these results.3,5,13,16,20 Our findings are
Table 3. Lung Cancer OR Estimates From Multinomial Logistic Regression Model
Lung Cancer
Histology
Fully Adjusted OR (95% CI) by Race/Ethnicity
PWhite Black Hispanic API AIAN Other
NSCLC 1.00 (Reference) 1.24 (0.85 to 1.80) 0.90 (0.51 to 1.56) 0.94 (0.53 to 1.68) 0.74 (0.23 to 2.41) 0.92 (0.44 to 1.90) .44
SCLC 1.00 (Reference) 0.65 (0.30 to 1.38) 0.57 (0.16 to 1.97) 1.03 (0.30 to 3.59) 2.52 (0.71 to 8.87) 1.27 (0.37 to 4.40)
NOTE. Estimates in model were adjusted for age, education, calcium supplementation, vitamin D supplementation, body mass index, age at start of smoking, duration of
smoking habit, pack-years of exposure, smoking status, alcohol use, membership in observational study, hormone replacement therapy or dietary modification or calcium/
vitaminD interventions, family history of cancer, oral contraceptive use, hormone use history, baseline physical activity, and diet (fruit, vegetable andmeat consumption). Data
are from the Women’s Health Initiative observational study and clinical trial cohorts.
Abbreviations: AIAN, American Indian/Alaskan Native; API, Asian/Pacific islander; NSCLC, non–small-cell lung cancer; OR, odds ratio; SCLC, small-cell lung cancer.
Table 4. Lung Cancer Mortality OR Estimates From Logistic Regression Models
Race/Ethnicity
Unadjusted Age Adjusted Age and Smoking
Adjusted
Fully Adjusted
OR (95% CI) P OR (95% CI) P OR (95% CI) OR (95% CI) P
White 1.00 (Reference) , .001 1.00 (Reference) , .001 1.00 (Reference) 1.00 (Reference) .22
Black 0.77 (0.56 to 1.05) 0.86 (0.63 to 1.18) 0.74 (0.54 to 1.01) 0.86 (0.62 to 1.18)
API 0.34 (0.16 to 0.75) 0.36 (0.16 to 0.77) 0.54 (0.25 to 1.17) 0.60 (0.28 to 1.31)
Hispanic 0.30 (0.15 to 0.62) 0.37 (0.18 to 0.76) 0.43 (0.21 to 0.89) 0.52 (0.26 to 1.07)
AIAN 1.66 (0.66 to 4.23) 1.85 (0.73 to 4.70) 1.62 (0.63 to 4.15) 1.59 (0.62 to 4.08)
Other 0.61 (0.24 to 1.53) 0.62 (0.24 to 1.57) 0.66 (0.26 to 1.66) 0.68 (0.27 to 1.70)
NOTE. Estimates in fully adjustedmodel were adjusted for age, education, calcium supplementation, vitamin D supplementation, bodymass index, age at start of smoking,
duration of smoking habit, pack-years of exposure, smoking status, alcohol use, membership in observational study, hormone replacement therapy or dietary modification or
calcium/vitamin D interventions, family history of cancer, oral contraceptive use, hormone use history, baseline physical activity, and diet (fruit, vegetable and meat
consumption). Data are from the Women’s Health Initiative observational study and clinical trial cohorts.
Abbreviations: AIAN, American Indian/Alaskan Native; API, Asian/Pacific islander; OR, odds ratio.
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also different from evaluations that demonstrate increased mor-
tality among API women compared with NHW women.39-41
Although we did not find decreased mortality for Hispanic
women compared with NHW women after adjustment for other
potential confounders, our study found that Hispanic women
continued to have a decreased mortality risk after age and smoking
adjustment; this finding is consistent with our previous findings
reporting survival advantages for this patient population.34 Similar
to a previous study,18 we found an independent association of
intensity of smoking and risk of lung cancer incidence and
mortality, however, we found no interaction of intensity of
smoking and race/ethnicity.
The various reasons for the differences noted in these studies
compared with ours most likely reflect the importance of evalu-
ating a wide variety of known risk factors cohesively in one data set.
Failure to include key risk factors may result in mis-specified
models that incorrectly attribute risk or advantage to members of
specific racial/ethnic groups. Our study, unlike previous evalua-
tions, comprehensively examined differences in lung cancer
incidence and mortality by race/ethnicity in the WHI, a rich set of
data that contains longitudinal and detailed information on smoking
history and duration of smoking habits; other behavioral factors,
such as diet, exercise, and vitamin and supplement intake; socio-
economic status; and demographic factors. In our fully adjusted
multivariablemodels, mortality differences were no longer significant
for any racial/ethnic group, nor were there differences when we
stratified by histology. Similar to findings from WHI studies that
evaluated disparities in other cancers,42 our results suggest that
differences in risk and mortality can be explained, at least in part, by
the effects of patient characteristics—mostly age and behavioral
characteristics, including smoking-related factors, diet, and BMI—on
lung cancer incidence and mortality.
The heterogeneity between results from other studies and
those from our study may also be due to differences in study
populations. The WHI study is comprised primarily of NHW
women; however, the recruited study population is reflective of the
racial/ethnic diversity in the United States at the time the study was
initiated. Among all racial and ethnic groups represented in the
WHI, women who self-select to participate in a longitudinal CT
Table 5. Covariate ORs From Incidence and Mortality Logistic Regression
Models
Characteristic
Incidence OR
(95% CI)
Mortality OR
(95% CI)
OS membership
No 1.00 (Reference) 1.00 (Reference)
Yes 0.99 (0.69 to 1.42) 0.90 (0.6 to 1.50)
HT membership
Not randomized 1.00 (Reference) 1.00 (Reference)
E + P control 1.21 (0.83 to 1.77) 0.99 (0.60 to 1.64)
E + P intervention 1.30 (0.90 to 1.89) 1.50 (0.94 to 2.37)
E-alone control 1.13 (0.74 to 1.72) 1.26 (0.75 to 2.14)
E-alone intervention 1.24 (0.82 to 1.87) 1.14 (0.67 to 1.95)
CaD membership
Not randomized 1.00 (Reference) 1.00 (Reference)
Control 0.99 (0.77 to 1.27) 1.03 (0.76 to 1.41)
Intervention 0.94 (0.73 to 1.21) 0.78 (0.56 to 1.09)
DM membership
Not randomized 1.00 (Reference) 1.00 (Reference)
Control 0.88 (0.63 to 1.23) 0.98 (0.64 to 1.49)
Intervention 0.79 (0.56 to 1.14) 0.84 (0.53 to 1.31)
Age, years
50-54 1.00 (Reference) 1.00 (Reference)
55-59 1.58 (1.13 to 2.20)* 1.59 (1.02 to 2.47)*
60-69 2.65 (1.96 to 3.60)* 2.65 (1.76 to 3.98)*
70-79 3.18 (2.29 to 4.42)* 3.80 (2.45 to 5.88)*
Education
None to high school graduate 1.00 (Reference) 1.00 (Reference)
Some postsecondary 0.95 (0.83 to 1.10) 0.88 (0.73 to 1.06)
Smoking status
Never 1.00 (Reference) 1.00 (Reference)
Current 2.26 (1.55 to 3.29)* 2.09 (1.28 to 3.39)*
Alcohol use
Nondrinker 1.00 (Reference) 1.00 (Reference)
Past drinker 1.05 (0.77 to 1.43) 1.17 (0.76 to 1.77)
, 1 drink/month 0.91 (0.65 to 1.26) 0.89 (0.56 to 1.41)
, 1 drink/week 1.08 (0.80 to 1.48) 1.22 (0.80 to 1.86)
1-6 drinks/week 1.03 (0.76 to 1.40) 1.15 (0.76 1.75)
$ 7 drinks/week 0.99 (0.72 to 1.37) 1.19 (0.77 to 1.83)
Postmenopausal HT
Never used 1.00 (Reference) 1.00 (Reference)
Past hormone 1.01 (0.86 to 1.18) 0.94 (0.77 to 1.16)
Current hormone 1.07 (0.91 to 1.24) 1.05 (0.86 to 1.28)
Oral contraceptive use
No 1.00 (Reference) 1.00 (Reference)
Yes 0.98 (0.85 to 1.12) 1.03 (0.86 to 1.23)
Family history of cancer
No 1.00 (Reference) 1.00 (Reference)
Yes 1.15 (1.01 to 1.32)* 1.09 (0.92 to 1.29)
Calcium supplementation
No 1.00 (Reference) 1.00 (Reference)
Yes 1.02 (0.83 to 1.24) 1.01 (0.78 to 1.30)
Vitamin D supplementation
No 1.00 (Reference) 1.00 (Reference)
Yes 0.94 (0.77 to 1.14) 0.96 (0.75 to 1.24)
Baseline MET-h/week
0 1.00 (Reference) 1.00 (Reference)
0-3 1.18 (0.96 to 1.45) 1.14 (0.88 to 1.48)
3-9 0.99 (0.82 to 1.20) 0.89 (0.70 to 1.13)
$ 9 1.00 (0.83 to 1.20) 0.85 (0.68 to 1.07)
BMI, kg/m2
, 25 1.00 (Reference) 1.00 (Reference)
25-30 0.77 (0.66 to 0.89)* 0.71 (0.58 to 0.85)*
$ 30 0.78 (0.66 to 0.92)* 0.74 (0.60 to 0.92)*
Age started smoking, years
Nonsmoker 1.00 (Reference) 1.00 (Reference)
, 20 0.77 (0.36 to 1.64) 0.70 (0.24 to 2.07)
$ 20 0.77 (0.36 to 1.63) 0.73 (0.25 to 2.17)
(continued in next column)
Table 5. Covariate ORs From Incidence and Mortality Logistic Regression
Models (continued)
Characteristic
Incidence OR
(95% CI)
Mortality OR
(95% CI)
Fruit portions consumed 0.94 (0.88 to 0.99)* 0.96 (0.89 to 1.04)
Vegetable portions consumed 0.97 (0.92 to 1.02) 0.91 (0.84 to 0.98)*
Animal protein consumed 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00)
Duration of smoking habit, years 1.03 (1.03 to 1.04)* 1.04 (1.02 to 1.05)*
Pack-year history
Nonsmoker 1.00 (Reference) 1.00 (Reference)
Heavy smoker 2.52 (1.17 to 5.44)* 3.12 (1.04 to 9.38)*
Light smoker 0.93 (0.44 to 1.97) 1.16 (0.40 to 3.42)
NOTE. Data are from the Women’s Health Initiative observational study and
clinical trial cohorts.
Abbreviations: AIAN, American Indian/Alaskan Native; API, Asian/Pacific
Islander; BMI, body mass index; CaD, calcium and vitamin D; DM, dietary
modification; E, estrogen; HT, hormone therapy; MET, metabolic equivalent; OR,
odds ratio; OS, observational study; P, progesterone.
*Significance of P , .05 and 95% CI does not cross or include 1.
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and OS may represent a group with increased health status and
education and with equal access to medical care. This level of access
to and interest in care may also explain our findings, among other
studies that examined cancer disparities in the WHI,42 which
showed no differences in tumor characteristics, such as stage and
histology at diagnosis, and which previous studies have demon-
strated are differential among NHB women who have limited
access to medical care.36,37 In addition, our low number of incident
cases in some racial and ethnic groups may have contributed to
wider CIs and decreased our ability to detect differences. However,
lung cancer incidence andmortality cases in theWHI cohort reflect
the general rates among the population of women at whole. The
low rates of lung cancer in our study, therefore, are not a limitation
of the sample but a direct reflection of the lower population
incidence and mortality rates in particular racial/ethnic
groups.1,8,33 The lack of additional information on women of
Hispanic and API origin, including the country of origin and place
of birth, limit our ability to evaluate whether the composition of
these groups contribute to differences between our results and
prior studies.43,44 Additionally, in our study, we were limited to
baseline smoking status and could not account for changes in exposure
during follow-up. This limitation may have caused misclassification
and biased our results toward the null. However, in a cohort pop-
ulation of postmenopausal women in the WHI, 99% of women
remained abstinent from smoking, and 60% of smokers continued to
smoke at 9 years follow-up,45 which suggests that the likely effect
of changes in smoking status during follow-up may be minimal.
Finally, we were unable to account for newer molecular and genetic
factors that may play a role in incidence and mortality for particular
racial/ethnic groups.46-48 The WHI Life and Longevity After Cancer
study,28 as well as recent cohort studies such as the United Kingdom
Biobank49 and European Prospective Investigations Into Cancer,50
may provide some associations of lifestyle behaviors, molecular and
genetic factors, and lung cancer incidence and mortality.
The strengths of our study include the prospective cohort
design, large cohort size, pathologic confirmation of lung cancer
diagnoses, detailed information on demographic and environ-
mental characteristics, and specificity of self-reported data. The
validated rich WHI database allowed us to study multiple cova-
riates that may influence lung cancer incidence and mortality
among racial and ethnic groups and that have not previously been
studied cohesively in one data set.
In conclusion, after adjustment for demographic, clinical,
and behavioral factors, Hispanic women had decreased lung
cancer incidence compared with NHW women; however, there
were no racial/ethnic differences in mortality. There is con-
siderable heterogeneity in the literature regarding these findings.
However, this study is the first to evaluate sociodemographic
and environmental covariates cohesively in one data set, and
such data in a prospective cohort are rare. The findings of this
study suggest that, although age is a significant risk factor,
modifiable exposures, such as smoking, are a major focus for
eliminating differences in the risk for and survival of lung cancer
for women.
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GLOSSARY TERM
non–small-cell lung cancer (NSCLC): a type of lung cancer that
includes squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma.
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